# ARASTEP: HCP commentary report

> 95 verified statements (35 from clinicians verified by NPI or staff page) from 17 commentary sources · 7 findings · updated Oct 31, 2026

## Report

- Trial: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
- NCT ID: NCT05794906
- Registry: https://clinicaltrials.gov/study/NCT05794906
- Sponsor: Bayer
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: darolutamide
- Indication: high-risk biochemical recurrence of prostate cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: c4ee715782df50d573c476db5b862291957bbbbfeb2b80d42439b0007893fa99

## Counts

- HCP commentary sources screened: 56
- Sources cited by verified statements: 19
- Verified statements: 95
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 35
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 20
- Voices cited: 19
- Cited voices identity-verified: 15

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ARASTEP asks whether adding darolutamide to ADT delays imaging-detected progression in high-risk biochemical recurrence of prostate cancer with PSMA-positive lesions and negative conventional imaging. Commentary comes from X threads, podcasts and YouTube discussions, including medical oncologists. The discussion turns on whether delaying PSMA-detected progression is clinically meaningful, whether an ARPI adds benefit after complete lesion ablation, and whether two years of hormonal therapy is optimal.

## Open Medical Affairs question

What added benefit from darolutamide, after any lesion-directed treatment and over a finite ADT course, would be clinically meaningful enough to justify its burden?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. PSMA positivity does not settle how much systemic treatment—or how urgently—to give
- F2. Local treatment is discussed alongside systemic therapy, while benefit after complete lesion ablation remains open
- F3. Two years is presented as a pragmatic middle course, not a proven optimal duration
- F4. Optimization can mean more or less treatment, but depends on recognizing risk correctly
- F5. Enzalutamide monotherapy is an alternative with its own benefit–harm trade-offs, not simply less treatment
- F6. PSMA-era relevance is a perceived strength, but imaging accuracy and clinically meaningful benefit remain separate questions
- F7. Enthusiasm is prospective and explicitly separated from a demonstrated ARASTEP benefit

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 9 | 9 | 3 | 6 | recorded | 3 |
| F2 | 17 | 13 | 5 | 5 | recorded | 3 |
| F3 | 7 | 6 | 3 | 2 | recorded | 3 |
| F4 | 12 | 11 | 5 | 5 | recorded | 4 |
| F5 | 5 | 3 | 1 | 2 | recorded | 3 |
| F6 | 24 | 20 | 12 | 10 | recorded | 3 |
| F7 | 9 | 9 | 8 | 7 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 3 | 4 | 0 | 1 | 1 | 9 | 3 | 2 posts and articles, 1 podcast or video | yes |
| F2 | 7 | 5 | 1 | 2 | 2 | 19 | 2 | 1 post or article, 4 podcasts and video | yes |
| F3 | 4 | 0 | 1 | 1 | 1 | 9 | 0 | 2 podcasts and video, 1 publication | yes |
| F4 | 7 | 1 | 1 | 0 | 3 | 15 | 2 | 2 posts and articles, 3 podcasts and video | yes |
| F5 | 3 | 1 | 0 | 0 | 1 | 5 | 0 | 1 podcast or video | yes |
| F6 | 13 | 2 | 0 | 1 | 8 | 26 | 0 | 5 posts and articles, 5 podcasts and video, 1 publication, 1 registry | yes |
| F7 | 5 | 2 | 0 | 0 | 2 | 11 | 0 | 4 posts and articles, 3 podcasts and video, 1 publication | yes |

### Trial dimensions

- Primary endpoint: Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR): F2 (1 shared claims), F6 (4 shared claims), F7 (1 shared claims)
- Secondary endpoints: F6 (1 shared claims)
- Population and setting: F2 (2 shared claims), F4 (1 shared claims), F6 (10 shared claims)
- The comparison: F1 (2 shared claims), F2 (3 shared claims), F7 (6 shared claims)
- Safety and tolerability: F5 (4 shared claims)
- Design and conduct: F2 (2 shared claims), F3 (1 shared claims), F6 (2 shared claims), F7 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Local treatment is discussed alongside systemic therapy, while benefit after complete lesion ablation remains open

A podcast exchange discussing ARASTEP asks whether adding an androgen-receptor pathway inhibitor to ADT benefits patients after radiation to every PSMA-detected oligometastatic lesion.

The source does not identify who asks the question about benefit after irradiation.

Source: podcast, 2025-05-14.

### F1. PSMA positivity does not settle how much systemic treatment—or how urgently—to give

An X thread discussing ARASTEP asks how much systemic intensification is needed in PSMA-positive recurrence and whether every PSMA-positive lesion reflects active cancer.

These are post dates for the thread; the individual questions are not separately dated.

Source: X thread, 2025-12-07.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 95 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 19 | Counts free |
| Speaker attribution for cited voices | 19 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR) | discussed | 5 | 4 |
| Secondary endpoints | discussed | 1 | 1 |
| Population and setting | discussed | 13 | 7 |
| The comparison | discussed | 9 | 8 |
| Safety and tolerability | discussed | 4 | 1 |
| Design and conduct | discussed | 6 | 4 |
| Finite treatment and the two-year rationale | discussed | 5 | 3 |
| SBRT, systemic therapy and benefit after lesion ablation | discussed | 18 | 6 |
| PSA kinetics, individualized selection and routine-care patterns | discussed | 8 | 4 |
| Stage migration, de-escalation and treatment urgency | discussed | 12 | 1 |
| Imaging access, referral and patient-centered treatment discussions | discussed | 9 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 47 | 9 |
| YouTube | 5 | 5 |
| Podcasts | 3 | 3 |
| Bluesky threads | 1 | 0 |
| Publications (primary source, cited for context) | not screened | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-03-23 to 2026-08-04
- Cited window: 2024-01-26 to 2026-01-09
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
- Registry: NCT05794906 (https://clinicaltrials.gov/study/NCT05794906)
- Study IDs: 21492 · 2022-501343-33-00 (CTIS (EU))
- Sponsor: Bayer
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 985 (actual)
- Start: 2023-04-03 (actual)
- Primary completion: 2027-07-30 (estimated)
- Primary endpoint: Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR) (After randomization to after last treatment, approximately 24 months)
- Intervention: Darolutamide (BAY1841788, Nubeqa) (drug)
- Intervention: Placebo matching darolutamide (other)
- Intervention: ADT (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about individualizing novel antiandrogen selection according to cardiac and neurological risk.
- Not yet captured in this edition: a view on individualized anti-androgen selection, practical ease of use, and patient discussion of benefits and adverse effects.
- Not yet captured in this edition: a view on treatment benefits, survival expectations and comparative toxicities of systemic options for high-risk biochemical recurrence.
- Not yet captured in this edition: a view on efficacy, survival qualifications and comparative toxicity when choosing systemic treatment for high-risk biochemical recurrence.
- Not yet captured in this edition: a view on toxicity-driven ADT interruption and combination treatment versus selective monotherapy in biochemical recurrence.
- Not yet captured in this edition: a view on toxicity-driven ADT interruption and hormonal monotherapy versus combination treatment in biochemical recurrence.
- Not yet captured in this edition: a remark on attribution of relayed commentary about trial design and potential practice change in biochemical recurrence.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 86 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are selective and do not establish the prevalence of any opinion among HCPs. Reposts, relayed discussions and repeated podcast/video formats are not independent clinical endorsements.
- Some connected treatment-selection remarks are missing. Several social-media passages and parts of recorded discussions were not fully assessed, so additional views and consequential qualifications may be absent.
- Discussion that does not name ARASTEP, or uses an unrecognized spoken variant, may be missing. Coverage of the clinical question is therefore not exhaustive.
- Not every named contributor has a documented clinical role. A profile's stated specialty or credential is not independent confirmation, and dated practice associations do not establish current employment.
- Unidentified recorded passages cannot be assigned to named participants from a program title, participant list or similar voice label.
- Presenting and steering-committee involvement are descriptions made by the sources; they do not independently validate a view or increase its evidentiary weight.
- The sources provide trial methods and prospective expectations, not ARASTEP efficacy or safety results. Observational signals, historical comparisons and estimates must not be substituted for its pending randomized answer.
- The methods context comes from registry information and a protocol publication rather than a separately listed full protocol document. No exact regulatory label was available to establish an approved indication for this regimen.
- Posting and publication dates locate statements, not trial readouts or changes of mind. Differences across cases and treatment settings should not automatically be called disagreement.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (95 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (15 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/arastep-nct05794906
- Agents: POST https://www.erudio.com/api/orders with {"report": "arastep-nct05794906", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=arastep-05794906

## Cite

Erudio Health. ARASTEP (NCT05794906): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/arastep-nct05794906

## Machine access

- JSON: https://www.erudio.com/reports/arastep-nct05794906.json
- Markdown: https://www.erudio.com/reports/arastep-nct05794906.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "arastep-05794906"}`